Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Key facts

Sponsor

Valneva Austria GmbH

Principal Investigator

Astrid Kaltenboeck, Ph.D.

Valneva Austria GmbH

Intervention

Japanese Encephalitis purified inactivated vaccine (IC51)(biological)

Enrollment

2675 enrolled

Eligibility

18 years · All sexes

Timeline

2005 – 2006

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Encephalitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07511049
  Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
  National Institute of Neurological Disorders and Stroke (NINDS)
• ACTIVE NOT RECRUITINGNCT07554261
  Clinical Features and Outcomes of VZV CNS Infections
  Kocaeli University
• RECRUITINGNCT07332234
  Optic Nerve Ultrasound for Assessing Cerebral Inflammation and Intracranial Hypertension in Cerebral Pathologies
  Spitalul Clinic de Boli Infecțioase și tropicale "Dr. Victor Babeș"
• ACTIVE NOT RECRUITINGNCT06820060
  Clinical Performance of QIAstat-Dx® Meningitis/Encephalitis (ME) Panel Plus
  QIAGEN Gaithersburg, Inc
• ACTIVE NOT RECRUITINGPHASE2NCT06899802
  A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine
  Bavarian Nordic
• RECRUITINGPHASE1, PHASE2NCT06680128
  A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
  SK Bioscience Co., Ltd.
• RECRUITINGNCT06368648
  CoMind Early Feasibility Study
  CoMind Technologies Limited
• ACTIVE NOT RECRUITINGPHASE4NCT06678373
  Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas
  Liaoning Chengda Biotechnology CO., LTD

See all trials for Encephalitis →